Navigation Links
Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
Date:6/21/2013

IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, today announced that its current investor group, including its newest investor Partners & Partners, has funded the third $10 million tranche that rounds out the total financing of $30 million initiated in December 2011. This financing was again triggered by the company's successful achievement of revenue milestones ahead of schedule.

(Logo: http://photos.prnewswire.com/prnh/20130319/LA79677LOGO)

The proceeds will be used to build out commercial infrastructure, accelerate the nationwide commercial launch, broaden third-party reimbursement and initiate foreign distribution of MIRISK VP™, Aviir's proprietary cardiac risk assessment technology, and additional laboratory testing services. Merck Global Health Innovation Fund led the round, and was joined by Partners & Partners. Current investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners also participated.

Douglas Harrington, M.D., CEO of Aviir commented, "Our pilot and regional launch programs have generated both enthusiastic response among the physician community and commercial adoption. The additional funding will now allow us to conduct a more broad commercial launch domestically and take the next steps toward a comprehensive international distribution plan to be rolled out later this year."

Harrington continued, "The MIRISK VP test determines an individual's risk of experiencing future cardiac events, enabling them to take preventive action before it is too late. 50% of people who have a heart attack have normal cholesterol levels, but cholesterol is only part of the risk equation. More than 70% of heart attacks are caused by the rupture of unstable plaque in the arteries, which leads to clotting and heart attacks. The MIRISK VP test serves as an early warning system that this condition may be present and, importantly, can be addressed."

Aviir's MIRISK VP technology consists of a simple blood test that can be ordered by doctors for their patients so they can understand their risk of experiencing a heart attack and be motivated to make therapeutic lifestyle changes. The MIRISK VP technology measures the blood levels of 7 proteins associated with the development of vulnerable plaque. It then uses a complex algorithm to analyze those results and other known risk factors to determine an individual's probability of experiencing a heart attack within the next five years. Aviir will also be offering cardiologists and primary care physicians of these high-risk patients individualized recommendations for lifestyle changes aimed at mitigating their risk and improving their heart health.

Inverness Advisors, a division of KEMA Partners LLC, acted as exclusive placement agent and Stradling Yocca Carlson & Rauth acted as legal counsel to Aviir for this financing and transaction.

About the MIRISK VP™ Assessment
The Aviir MIRISK VP Assessment was developed out of basic research at the Stanford University School of Medicine. Researchers identified proteins associated with the biological processes underlying vulnerable plaque development and showed they could be measured in a patient's blood up to 5 years prior to a plaque rupture and the ensuing heart attack. Aviir's scientists developed sensitive multiplexed assays to measure proteins in a person's serum and an algorithm that combines the levels of those proteins with other clinical risk factors into the MIRISK VP Assessment to provide an absolute risk score for CHD risk. That algorithm has been shown in an independent study population to significantly reclassify intermediate risk individuals into their true risk category. By objectively classifying those patients at high risk, the Aviir MIRISK VP Assessment supports physicians to more effectively manage and treat this group – aiding in the reduction and prevention of cardiac events. Used in conjunction with other clinical information, the MIRISK VP Assessment's easy to understand risk score for the imminent 5-year horizon may motivate compliance and behavioral changes by patients previously misidentified as intermediate risk.

About Aviir
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

Company Contacts:

For Investor Relations, please contact:
Matt Clawson
Life Capital Partners
949.370.8500

For media inquiries, please contact:
Tamara York
Tamara York Public Relations, LLC
212.967.8300


'/>"/>
SOURCE Aviir Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aviir Secures Second $10 Million Financing Tranche; Attracts New Investor Group
2. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
3. United Spinal Secures Victory in Protecting Access to Complex Rehab Technology in Washington State
4. Alimera Sciences Secures $20 Million Debt Facility
5. Henry Schein Secures $300 Million Of Committed Financing
6. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
7. Cell Therapeutics Secures $15 Million Loan Financing Agreement
8. Neuralstem Secures $8 Million In Debt Financing From Hercules
9. Total Artificial Heart Manufacturer SynCardia Secures $19M Financing
10. Medical Equipment Solutions Secures GSA Schedule, Will Service VA and Federal Agencies
11. High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... 18, 2017  Tarix Orphan LLC today announced that ... Rare Pediatric Disease (RPD) designation for the company,s drug ... Bullosa (RDEB), a rare genetic skin disorder. There are ... limited to supportive care. "The RPD designation ... previously granted by the FDA in this indication," said ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... At Hallmark Nameplate, ... announce that they have achieved certification to ISO 13485. This certification is another way ... up to date products and services that they need. , The ISO 13485 Certification ...
(Date:1/18/2017)... NH (PRWEB) , ... January 18, 2017 , ... ... launch of the revolutionary Active Brake Technology (ABT), an innovative braking system that ... , Active Brake Technology addresses one of the biggest concerns of beginner and ...
(Date:1/17/2017)... NY (PRWEB) , ... January 17, 2017 , ... Gym ... opening of a new showroom at South Dixie Hwy in Miami, FL. , “We ... at Gym Source. “The new innovative in-store concept is designed to give clients a ...
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for Pink ... Pink Elephant recognizes a new product or service developed by an IT services vendor ... The award highlights original innovations that were released in 2016, either as a major ...
(Date:1/17/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , ... Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as ...
Breaking Medicine News(10 mins):